dc.contributorPharmacological Research in Dentistry Group, Faculty of Dentistry, University of Granada
dc.contributorExtremadura Health Service, Cáceres Health Center Area SES
dc.contributorFaculty of Odontology of Araçatuba, University of the State of São Paulo
dc.contributorFaculty of Medicine and Dentistry, University of Murcia
dc.date.accessioned2022-04-28T18:59:58Z
dc.date.accessioned2022-12-20T00:56:09Z
dc.date.available2022-04-28T18:59:58Z
dc.date.available2022-12-20T00:56:09Z
dc.date.created2022-04-28T18:59:58Z
dc.date.issued2014-01-01
dc.identifierEuropean Review for Medical and Pharmacological Sciences, v. 18, n. 9, p. 1391-1397, 2014.
dc.identifier1128-3602
dc.identifierhttp://hdl.handle.net/11449/220174
dc.identifier2-s2.0-84902136491
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/5400303
dc.description.abstractBisphosphonates are a type of drugs known to inhibit bone resorption through complex interventions. Their primary mechanism of action is aimed at the cellular level, inhibiting osteoclast activity and, thus, bone resorption. Bisphosphonates are, therefore, very widely used, with many patients receiving continuous treatment for years. But it is well known that these drugs can produce osteonecrosis of the jaw and this is their principal risk. A 75-year-old woman received dental treatment before starting intravenous BP therapy for a breast cancer. She started intravenous bisphosphonate treatment with monthly protocol and after two years the patient presented a wound compatible with osteonecrosis of the jaw.
dc.languageeng
dc.relationEuropean Review for Medical and Pharmacological Sciences
dc.sourceScopus
dc.subjectBisphosphonates
dc.subjectChlorhexidine
dc.subjectOsteonecrosis of the jaw
dc.titleBisphosphonate-associated osteonecrosis of the jaw 2 years after teeth extractions: A case report solved with non-invasive treatment
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución